ロード中...
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic co...
保存先:
| 出版年: | Front Neurosci |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367528/ https://ncbi.nlm.nih.gov/pubmed/25852463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnins.2015.00092 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|